%PDF-1.7 1 0 obj << /Type /Catalog /Outlines 2 0 R /Pages 3 0 R >> endobj 2 0 obj << /Type /Outlines /Count 0 >> endobj 3 0 obj << /Type /Pages /Kids [6 0 R 13 0 R ] /Count 2 /Resources << /ProcSet 4 0 R /Font << /F1 8 0 R /F2 9 0 R /F3 10 0 R >> /ExtGState << /GS1 11 0 R /GS2 12 0 R >> >> /MediaBox [0.000 0.000 595.280 841.890] >> endobj 4 0 obj [/PDF /Text ] endobj 5 0 obj << /Producer (dompdf 3.1.0 + CPDF) /CreationDate (D:20260403094305+00'00') /ModDate (D:20260403094305+00'00') >> endobj 6 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Contents 7 0 R >> endobj 7 0 obj << /Length 5089 >> stream 0.000 0.000 0.000 rg BT 35.000 797.842 Td /F1 19.5 Tf [(Treadwell Therapeutics Announces A Presentation at the 2022)] TJ ET BT 35.000 774.033 Td /F1 19.5 Tf [(SABCS Annual Meeting Featuring a Clinical Trial Update on)] TJ ET BT 35.000 750.223 Td /F1 19.5 Tf [(CFI-402257, a Best-in-Class TTK inhibitor)] TJ ET BT 35.000 710.207 Td /F3 14.0 Tf [(Description)] TJ ET BT 35.000 669.017 Td /F1 12.0 Tf [(NEW YORK, Dec. 9, 2022 /PRNewswire/ ?? Treadwell Therapeutics, a clinical-stage biotechnology)] TJ ET BT 35.000 654.365 Td /F1 12.0 Tf [(company developing novel medicines for highly aggressive cancers, today announced that data)] TJ ET BT 35.000 639.713 Td /F1 12.0 Tf [(presented on the ongoing CFI-402257-CL-001 clinical study of the Company??s CFI-402257 program)] TJ ET BT 35.000 625.061 Td /F1 12.0 Tf [(in advanced solid tumors, continued to show a tolerable safety profile and demonstrated clinical benefit)] TJ ET BT 35.000 610.409 Td /F1 12.0 Tf [(both as a monotherapy as well in combination with fulvestrant. Data were presented at the 2022 San)] TJ ET BT 35.000 595.757 Td /F1 12.0 Tf [(Antonio Breast Cancer Symposium \(SABCS\) being held from December 6-10, 2022 at the Henry B.)] TJ ET BT 35.000 581.105 Td /F1 12.0 Tf [(Gonzalez Convention Center in San Antonio, Texas.)] TJ ET BT 35.000 554.453 Td /F1 12.0 Tf [(??CFI-402257 is well-tolerated and showed signs of anti-tumor activity either as a monotherapy or in)] TJ ET BT 35.000 539.801 Td /F1 12.0 Tf [(combination with Fulvestrant, including some patients who were with durable disease control after)] TJ ET BT 35.000 525.149 Td /F1 12.0 Tf [(progression on prior CDK4/6 inhibitor therapy?)] TJ ET BT 289.100 525.149 Td /F1 12.0 Tf [()] TJ ET BT 292.436 525.149 Td /F1 12.0 Tf [( said Dr. Philippe Bedard, Study investigator and)] TJ ET BT 35.000 510.497 Td /F1 12.0 Tf [(Associate Professor of Medicine at the University of Toronto and Staff Medical Oncologist at the)] TJ ET BT 35.000 495.845 Td /F1 12.0 Tf [(Princess Margaret Cancer Centre, Toronto, Canada.)] TJ ET BT 35.000 469.193 Td /F1 12.0 Tf [(??CFI-402257 continues to demonstrate an encouraging clinical profile, and we look forward to further)] TJ ET BT 35.000 454.541 Td /F1 12.0 Tf [(developing the molecule for the treatment of ER+ breast cancer,?)] TJ ET BT 388.844 454.541 Td /F1 12.0 Tf [()] TJ ET BT 392.180 454.541 Td /F1 12.0 Tf [( added Dr. Michael Tusche,)] TJ ET BT 35.000 439.889 Td /F1 12.0 Tf [(Treadwell co-CEO.)] TJ ET BT 35.000 413.237 Td /F1 12.0 Tf [(2022 SABCS Poster Presentations and Details:)] TJ ET 0.000 0.000 0.000 RG 0.6 w 0 J [ ] 0 d 35.000 410.627 m 287.120 410.627 l S BT 35.000 386.585 Td /F1 12.0 Tf [(An Update to a Phase I Trial of CFI-402257, an oral TTK Inhibitor, in Patients with Advanced Solid)] TJ ET BT 35.000 371.933 Td /F1 12.0 Tf [(Tumors with HER2-Negative Breast Cancer Expansion Cohorts)] TJ ET BT 35.000 345.281 Td /F1 12.0 Tf [(Poster Number: P6-10-13)] TJ ET BT 35.000 318.629 Td /F1 12.0 Tf [(Date: December 9th, 7:00 am CT)] TJ ET BT 35.000 291.977 Td /F1 12.0 Tf [(Data presented on CFI-402257, an oral, best-in-class TTK inhibitor, continue to show a tolerable safety)] TJ ET BT 35.000 277.325 Td /F1 12.0 Tf [(profile at the recommended Phase 2 dose of 168 mg once daily with manageable, dose-dependent)] TJ ET BT 35.000 262.673 Td /F1 12.0 Tf [(neutropenia being the primary toxicity. In this heavily pre-treated population \(N=86\), the overall)] TJ ET BT 35.000 248.021 Td /F1 12.0 Tf [(response rate was 6% for monotherapy patients \(4/66\) and 10% for ER+/HER2- breast cancer patients)] TJ ET BT 35.000 233.369 Td /F1 12.0 Tf [(treated in combination with fulvestrant \(2/20\). The clinical benefit rate \(CR+PR+SD>6 months\) for)] TJ ET BT 35.000 218.717 Td /F1 12.0 Tf [(monotherapy and combination were 12% and 25%, respectively. Patients achieving stable disease or)] TJ ET BT 35.000 204.065 Td /F1 12.0 Tf [(better stayed on treatment for a median of 242 days \(range: 112 to 673\). Significantly, several ER+)] TJ ET BT 35.000 189.413 Td /F1 12.0 Tf [(breast cancer patients who previously failed CDK4/6 inhibitors in the combination cohort remained on)] TJ ET BT 35.000 174.761 Td /F1 12.0 Tf [(therapy for a year or more. The most common drug related toxicities of any grade, which occurred in)] TJ ET BT 35.000 160.109 Td /F1 12.0 Tf [(greater than 10% of all patients, included fatigue \(48%\), nausea \(48%\), decreased appetite \(34%\),)] TJ ET BT 35.000 145.457 Td /F1 12.0 Tf [(diarrhea \(34%\), vomiting \(24%\), constipation \(21%\) and headache \(21%\).)] TJ ET BT 35.000 114.772 Td /F3 14.0 Tf [(About Treadwell Therapeutics)] TJ ET q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 1)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 8 0 obj << /Type /Font /Subtype /Type1 /Name /F1 /BaseFont /Helvetica /Encoding /WinAnsiEncoding >> endobj 9 0 obj << /Type /Font /Subtype /Type1 /Name /F2 /BaseFont /Times-Roman /Encoding /WinAnsiEncoding >> endobj 10 0 obj << /Type /Font /Subtype /Type1 /Name /F3 /BaseFont /Helvetica-Bold /Encoding /WinAnsiEncoding >> endobj 11 0 obj << /Type /ExtGState /BM /Normal /CA 1 >> endobj 12 0 obj << /Type /ExtGState /BM /Normal /ca 1 >> endobj 13 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Annots [ 15 0 R 17 0 R ] /Contents 14 0 R >> endobj 14 0 obj << /Length 1992 >> stream 0.000 0.000 0.000 rg BT 35.000 820.168 Td /F1 12.0 Tf [(Treadwell Therapeutics is a science driven, clinical-stage, multi-modality biotechnology company)] TJ ET BT 35.000 805.516 Td /F1 12.0 Tf [(developing first-in-class and best-in-class medicines to address unmet needs in patients with cancer.)] TJ ET BT 35.000 790.864 Td /F1 12.0 Tf [(The Company??s internally developed clinical pipeline includes CFI-400945, CFI-402257 \(TTK)] TJ ET BT 35.000 776.212 Td /F1 12.0 Tf [(inhibitor\) and CFI-402411 \(HPK1 inhibitor\). The company is also advancing a pre-clinical pipeline of)] TJ ET BT 35.000 761.560 Td /F1 12.0 Tf [(first-in-class antibody and TCR-based cell therapy assets. For more information, please visit)] TJ ET BT 35.000 746.908 Td /F1 12.0 Tf [(www.treadwelltx.com.)] TJ ET BT 35.000 716.224 Td /F3 14.0 Tf [(Contact)] TJ ET BT 35.000 687.034 Td /F1 12.0 Tf [(Investors:)] TJ ET 0.000 0.000 0.000 RG 0.6 w 0 J [ ] 0 d 35.000 684.424 m 87.020 684.424 l S 0.000 0.000 0.800 rg BT 35.000 672.382 Td /F1 12.0 Tf [(ir@treadwelltx.com)] TJ ET 0.000 0.000 0.800 RG 35.000 669.772 m 137.192 669.772 l S 0.000 0.000 0.000 rg BT 35.000 645.730 Td /F1 12.0 Tf [(General inquiries:)] TJ ET 0.000 0.000 0.000 RG 35.000 643.120 m 129.032 643.120 l S 0.000 0.000 0.800 rg BT 35.000 631.078 Td /F1 12.0 Tf [(info@treadwelltx.com)] TJ ET 0.000 0.000 0.800 RG 35.000 628.468 m 149.876 628.468 l S 0.000 0.000 0.000 rg BT 35.000 604.426 Td /F3 12.0 Tf [(Date Created)] TJ ET BT 35.000 589.774 Td /F1 12.0 Tf [(December 9, 2022)] TJ ET q 35.000 586.843 0.000 0.000 re W n Q /GS1 gs /GS2 gs q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 2)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 15 0 obj << /Type /Annot /Subtype /Link /F 28 /A 16 0 R /Border [0 0 0] /H /I /Rect [ 35.0000 670.0506 137.1920 682.2606 ] >> endobj 16 0 obj << /Type /Action /S /URI /URI (mailto:ir@treadwelltx.com) >> endobj 17 0 obj << /Type /Annot /Subtype /Link /F 28 /A 18 0 R /Border [0 0 0] /H /I /Rect [ 35.0000 628.7466 149.8760 640.9566 ] >> endobj 18 0 obj << /Type /Action /S /URI /URI (mailto:info@treadwelltx.com) >> endobj xref 0 19 0000000000 65535 f 0000000009 00000 n 0000000074 00000 n 0000000120 00000 n 0000000344 00000 n 0000000373 00000 n 0000000522 00000 n 0000000625 00000 n 0000005766 00000 n 0000005873 00000 n 0000005982 00000 n 0000006095 00000 n 0000006152 00000 n 0000006209 00000 n 0000006340 00000 n 0000008385 00000 n 0000008518 00000 n 0000008595 00000 n 0000008728 00000 n trailer << /Size 19 /Root 1 0 R /Info 5 0 R /ID[] >> startxref 8807 %%EOF